Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Ophthalmology

Long-Term Monitoring and Complications

At a Glance

Long-term hypoparathyroidism care relies on regular blood tests and urine calcium checks, with kidney ultrasounds, eye exams, or other imaging when indicated. Monitoring helps identify kidney, brain, eye, and bone complications, while testing becomes more frequent after medication changes.

While the daily management of hypoparathyroidism focuses on preventing symptoms like tingling and cramps, long-term care is about protecting your organs from the effects of mineral imbalances. Because this condition forces you to bypass your body’s natural “calcium thermostat,” even small imbalances over many years can affect your kidneys, brain, eyes, and bones [1][2].

Protecting Your Kidneys

The kidneys are the organs most at risk in chronic hypoparathyroidism. Because you lack the hormone that tells your kidneys to save calcium, much of the calcium you take in supplements “leaks” into your urine [3][4].

Over time, this can lead to several complications. Observational studies comparing patients with hypoparathyroidism to the general population have shown higher relative risks for:

  • Nephrolithiasis: Kidney stones. Patients with this condition may have a higher risk of developing stones [5][6].
  • Nephrocalcinosis: Tiny calcium deposits that form within the kidney tissue itself [5]. This risk is significantly elevated in patients with chronic hypoparathyroidism [5].
  • Chronic Kidney Disease (CKD): Continuous stress on the kidneys can lead to a permanent loss of function. Research shows patients have a higher relative risk of developing CKD and progressing to end-stage kidney disease [7][5].

Note: These are risks, not certainties, and absolute risk depends heavily on how well your urine calcium is managed.

Complications in the Brain and Eyes

Mineral imbalances can also lead to the buildup of calcium in other parts of the body.

Basal Ganglia Calcification

The basal ganglia are structures deep in the brain that help control movement and mood [8]. Over time, calcium can deposit in these areas, particularly in people with nonsurgical (genetic or autoimmune) forms of the disease [9]. While these deposits are sometimes “silent” and cause no symptoms, they can be associated with seizures, movement disorders (like tremors or stiffness), or changes in memory and mood [8][10].

Cataracts

People with chronic hypoparathyroidism have a higher risk of developing a specific type of cataract (clouding of the eye lens) [11]. In one large registry, nearly 1 in 10 patients had cataracts, and the risk increased significantly the longer a person had the disease [12][13].

Bone Quality and Fracture Risk

In most people, bones are constantly being broken down and rebuilt. In hypoparathyroidism, this “remodeling” process slows down significantly [14].

This creates a unique situation: your bone mineral density (BMD) on a DXA scan may appear very high—sometimes even “better than normal” [14]. However, high density does not always mean high quality, as DXA does not capture every aspect of bone strength. Because the bone isn’t being “refreshed” regularly, its quality can be altered [14][15]. Some studies show an increased risk of vertebral (spine) fractures, particularly in those with nonsurgical causes, but the relationship between this low-turnover state and fracture risk is complex and varies by patient [16][17].

Your Recommended Monitoring Schedule

Monitoring depends on stability, recent dose changes, kidney findings, symptoms, local guidance, and your treatment. The schedule below outlines common practices [18][19].

Routine Blood Tests

Once your medication doses are stable, blood is often drawn at least twice a year to check [1][2]:

  • Albumin-adjusted calcium (targeting the low-normal range) [1].
  • Phosphorus and Magnesium [2].
  • Creatinine/eGFR to monitor kidney filtration [2][20].
  • 25-OH Vitamin D [2].

Annual and Periodic Testing

  • 24-Hour Urine Collection: Often done yearly to monitor how much calcium your kidneys are losing. It helps your doctor decide if your medication needs to be lowered or if you need a “kidney-sparing” medication like a thiazide diuretic [2][21][22].
  • Renal Ultrasound: Often obtained at baseline and repeated when clinically indicated (sometimes every 1 to 3 years) to look for new stones or signs of calcification [2][20].
  • Eye Exams: Routine ophthalmology check-ups should be individualized to help detect cataracts early [11].
  • Imaging for Brain or Bone: These are not usually routine but may be ordered if you develop new symptoms like tremors, memory issues, or back pain [8][23].

Note: If your medications are changed, your blood tests will likely be repeated much more frequently—often within 1 to 2 weeks—until your levels are stable again [22][1].

Common questions in this guide

How often do I need blood tests when my hypoparathyroidism treatment is stable?
When medication doses are stable, blood tests are often done at least twice a year. They may check calcium, phosphorus, magnesium, kidney filtration, and vitamin D; after a medication change, testing is usually more frequent until levels stabilize.
Why is a 24-hour urine calcium test part of hypoparathyroidism monitoring?
It measures how much calcium your kidneys remove in a day. The result helps your clinician assess kidney-stone risk and decide whether calcium treatment should be adjusted or a thiazide water pill might help lower urinary calcium.
What kidney problems can chronic hypoparathyroidism cause?
Chronic hypoparathyroidism can be associated with kidney stones, calcium deposits inside kidney tissue, and chronic kidney disease. These are risks rather than certainties, and the chance depends in part on how well urine calcium is controlled.
Does high bone density on a DXA scan mean my fracture risk is low?
Hypoparathyroidism slows normal bone remodeling, so a DXA scan may show high bone mineral density. DXA does not capture every aspect of bone quality, so a high result does not automatically mean your bones are stronger or that fracture risk is low.
How often should I have eye exams with chronic hypoparathyroidism?
Chronic hypoparathyroidism is associated with a higher risk of cataracts, which are clouding of the eye lens, and the risk may increase with longer disease duration. Your clinician can individualize ophthalmology visits to look for early lens changes and other vision problems.
What symptoms could lead to testing for calcium deposits in the brain?
New tremors, stiffness, seizures, or changes in memory or mood may prompt a clinician to consider evaluation for calcium deposits in deep brain structures. Brain imaging is not usually routine, so the decision depends on your symptoms and medical history.
When might I need a kidney ultrasound for hypoparathyroidism?
A kidney ultrasound is often done at baseline and repeated when clinically indicated; some care plans repeat it every one to three years. It looks for new kidney stones or calcium deposits, but timing depends on kidney findings, symptoms, treatment, and local guidance.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How often should I have blood tests for my calcium, phosphate, and kidney function now that my doses are stable?
  2. 2.Since I have chronic hypoparathyroidism, when should I have my next renal ultrasound to check for stones or calcification?
  3. 3.Does my high bone density on a DXA scan accurately reflect my actual fracture risk?
  4. 4.Should I see an ophthalmologist for a specialized eye exam to check for 'posterior subcapsular cataracts'?
  5. 5.If I start having symptoms like tremors or memory issues, would you recommend a brain CT scan to check for basal ganglia calcification?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Management of Hypoparathyroidism.

    Khan AA, Guyatt G, Ali DS, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2022; (37(12)):2663-2677 doi:10.1002/jbmr.4716.

    PMID: 36161671
  2. 2

    Initial Assessment and Monitoring of Patients with Chronic Hypoparathyroidism: A Systematic Current Practice Survey.

    Van Uum S, Shrayyef M, M'Hiri I, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2022; (37(12)):2630-2641 doi:10.1002/jbmr.4698.

    PMID: 36066096
  3. 3

    Current treatment of hypoparathyroidism: Theory versus reality waiting guidelines for children and adolescents.

    Di Maio S, Soliman AT, De Sanctis V, Kattamis CC

    Acta bio-medica : Atenei Parmensis 2018; (89(1)):122-131 doi:10.23750/abm.v89i1.7118.

    PMID: 29633734
  4. 4

    Defining the syndromes of parathyroid failure after total thyroidectomy.

    Lorente-Poch L, Sancho JJ, Muñoz-Nova JL, et al.

    Gland surgery 2015; (4(1)):82-90 doi:10.3978/j.issn.2227-684X.2014.12.04.

    PMID: 25713783
  5. 5

    Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study.

    Ketteler M, Chen K, Gosmanova EO, et al.

    Advances in therapy 2021; (38(4)):1946-1957 doi:10.1007/s12325-021-01649-2.

    PMID: 33704680
  6. 6

    Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism.

    Gosmanova EO, Houillier P, Rejnmark L, et al.

    Reviews in endocrine & metabolic disorders 2021; (22(2)):297-316 doi:10.1007/s11154-020-09613-1.

    PMID: 33599907
  7. 7

    Risk of Chronic Kidney Disease and Estimated Glomerular Filtration Rate Decline in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study.

    Gosmanova EO, Chen K, Rejnmark L, et al.

    Advances in therapy 2021; (38(4)):1876-1888 doi:10.1007/s12325-021-01658-1.

    PMID: 33687651
  8. 8

    Hypoparathyroidism and Fahr's syndrome: case series.

    Arruda ACG, Guerra ACDZ, Pessoa CH, et al.

    Jornal brasileiro de nefrologia 2022; (44(4)):592-596 doi:10.1590/2175-8239-JBN-2020-0243.

    PMID: 34224552
  9. 9

    Basal Ganglia Calcification Is Associated With Local and Systemic Metabolic Mechanisms in Adult Hypoparathyroidism.

    Zavatta G, Tebben PJ, McCollough CH, et al.

    The Journal of clinical endocrinology and metabolism 2021; (106(7)):1900-1917 doi:10.1210/clinem/dgab162.

    PMID: 33788935
  10. 10

    Basal ganglia calcification in hypoparathyroidism and pseudohypoparathyroidism: local and systemic metabolic mechanisms.

    Zavatta G, Clarke BL

    Journal of endocrinological investigation 2021; (44(2)):245-253 doi:10.1007/s40618-020-01355-w.

    PMID: 32661948
  11. 11

    Complications, Symptoms, Presurgical Predictors in Patients With Chronic Hypoparathyroidism: A Systematic Review.

    Yao L, Hui X, Li M, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2022; (37(12)):2642-2653 doi:10.1002/jbmr.4673.

    PMID: 36375810
  12. 12

    The Russian Registry of Chronic Hypoparathyroidism.

    Kovaleva EV, Eremkina AK, Elfimova AR, et al.

    Frontiers in endocrinology 2022; (13()):800119 doi:10.3389/fendo.2022.800119.

    PMID: 35250859
  13. 13

    Increased mortality and morbidity in patients with chronic hypoparathyroidism: A population-based study.

    Vadiveloo T, Donnan PT, Leese CJ, et al.

    Clinical endocrinology 2019; (90(2)):285-292 doi:10.1111/cen.13895.

    PMID: 30375660
  14. 14

    Bone imaging in hypoparathyroidism.

    Silva BC, Rubin MR, Cusano NE, Bilezikian JP

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2017; (28(2)):463-471 doi:10.1007/s00198-016-3750-0.

    PMID: 27577725
  15. 15

    Bone quality in hypoparathyroidism.

    Tay YD, Tabacco G, Bilezikian JP

    Minerva endocrinology 2021; (46(3)):325-334 doi:10.23736/S2724-6507.21.03527-2.

    PMID: 34014065
  16. 16

    Fracture risk in hypoparathyroidism: a systematic review and meta-analysis.

    Pal R, Bhadada SK, Mukherjee S, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2021; (32(11)):2145-2153 doi:10.1007/s00198-021-05966-8.

    PMID: 34021765
  17. 17

    Vertebral fractures, trabecular bone score and their determinants in chronic hypoparathyroidism.

    Saha S, Mannar V, Kandasamy D, et al.

    Journal of endocrinological investigation 2022; (45(9)):1777-1786 doi:10.1007/s40618-022-01818-2.

    PMID: 35585296
  18. 18

    Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop.

    Khan AA, Bilezikian JP, Brandi ML, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2022; (37(12)):2568-2585 doi:10.1002/jbmr.4691.

    PMID: 36054621
  19. 19

    Best practice recommendations for the diagnosis and management of hypoparathyroidism.

    Khan AA, Ali DS, Bilezikian JP, et al.

    Metabolism: clinical and experimental 2025; (171()):156335 doi:10.1016/j.metabol.2025.156335.

    PMID: 40581321
  20. 20

    Renal complications in chronic hypoparathyroidism - a systematic cross-sectional assessment.

    Gronemeyer K, Fuss CT, Hermes F, et al.

    Frontiers in endocrinology 2023; (14()):1244647 doi:10.3389/fendo.2023.1244647.

    PMID: 38027217
  21. 21

    UK national chronic hypoparathyroidism audit.

    Kiam JS, Sharma V, Glenister L, et al.

    Clinical endocrinology 2022; (97(5)):562-567 doi:10.1111/cen.14798.

    PMID: 35792134
  22. 22

    Hydrochlorothiazide with salt restriction in nonsurgical hypoparathyroidism: a placebo-controlled single-blinded randomized crossover trial assessing efficacy and safety.

    Jha V, Mukherjee S, Bhadada SK, et al.

    JBMR plus 2025; (9(12)):ziaf174 doi:10.1093/jbmrpl/ziaf174.

    PMID: 41293325
  23. 23

    Skeletal health status among patients with chronic hypoparathyroidism: results from the Canadian National Hypoparathyroidism Registry (CNHR).

    Khan AA, AbuAlrob H, Ali DS, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2025; (36(4)):673-684 doi:10.1007/s00198-025-07410-7.

    PMID: 39955688

This page is for informational purposes only and does not constitute medical advice. Your healthcare team should personalize hypoparathyroidism monitoring, testing, and treatment for your situation.

Get notified when new evidence is published on Hypoparathyroidism.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.